RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

23 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

07 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

06 Apr 2025 12:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

20 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

19 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

18 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

26 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

13 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

10 Jan 2025 07:15:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

20 Dec 2024 14:15:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

03 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 Nov 2024 18:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 Oct 2024 08:00:01 By Nasdaq GlobeNewswire